LAVA Therapeutics NV
LVTXDelisted Nov 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840748
LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.
13F holders, Q1 2025
Institutional positions in LAVA Therapeutics NV as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −2 vs. Q4 2024
- Shares held
- 8.04M
- +1.57M (+24.3%) vs. Q4 2024
- Total value
- $10.2M
- +$4.06M (+66.0%) vs. Q4 2024
- New holders
- 6
- 3 more added
- Sold out
- 8
- 3 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 21 | $16.1M |
| Q2 2025 | 19 | $10.6M |
| Q1 2025 | 20 | $10.2M |
| Q4 2024 | 22 | $6.15M |
| Q3 2024 | 21 | $5.99M |
| Q2 2024 | 19 | $6.77M |
| Q1 2024 | 20 | $12.5M |
| Q4 2023 | 14 | $9.22M |
| Q3 2023 | 14 | $8.47M |
| Q2 2023 | 15 | $11.7M |
| Q1 2023 | 19 | $11.2M |
| Q4 2022 | 20 | $26.3M |
| Q3 2022 | 13 | $34.1M |
| Q2 2022 | 17 | $22.8M |
| Q1 2022 | 18 | $35.2M |
| Q4 2021 | 20 | $44.3M |
| Q3 2021 | 19 | $48.6M |
| Q2 2021 | 18 | $95.5M |
| Q1 2021 | 24 | $139.1M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Redmile Group, LLC | 2,074,372 | $2.63M | 0.25% | 00.0% | Unchanged |
| BML Capital Management, LLC | 1,960,610 | $2.49M | 2.02% | +1,960,610 | New |
| Sanofi | 1,919,455 | $2.44M | 1.47% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,149,345 | $1.46M | 0.89% | 00.0% | Unchanged |
| Bruce & Co., Inc. | 521,874 | $662.8K | 0.21% | −250,000−32.4% | Reduced |
| Pathway Financial Advisors LLC | 102,500 | $130.2K | 0.02% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 65,000 | $82.5K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 57,715 | $73.3K | 0.00% | +8,943+18.3% | Added |
| Sphera Funds Management Ltd. | 48,420 | $61.5K | 0.02% | −77,908−61.7% | Reduced |
| BNP Paribas Arbitrage, SA | 45,300 | $57.5K | 0.00% | +3,500+8.4% | Added |
| XTX Topco Ltd | 24,307 | $30.9K | 0.00% | +24,307 | New |
| Lepercq De Neuflize Asset Management LLC | 23,000 | $29.2K | 0.03% | +23,000 | New |
| UBS Group AG | 16,895 | $21.5K | 0.00% | −1,536−8.3% | Reduced |
| Geode Capital Management, LLC | 16,164 | $20.5K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 11,800 | $15.0K | 0.00% | +3,300+38.8% | Added |
| Citadel Advisors LLC | 5,023 | $6.38K | 0.00% | +5,023 | New |
| JPMorgan Chase & Co | 1,300 | $1.65K | 0.00% | +1,300 | New |
| Advisor Group Holdings, Inc. | 1,110 | $1.41K | 0.00% | +1,110 | New |
| TSFG, LLC | 400 | $1.00K | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 300 | $381 | 0.00% | 00.0% | Unchanged |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −31,985−100.0% | Sold out |
| Diadema Partners LP | 0 | $0 | 0.00% | −21,508−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −19,916−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −19,604−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −17,836−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −13,157−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −6,000−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −20−100.0% | Sold out |